“Using Synthetic Biology to Battle Mpox”
September 9, 2024
Tonix Pharmaceuticals has unveiled data on its mpox vaccine platform at a symposium honoring collaborator Dr. David Evans at the University of Alberta. The presentation, "Using Synthetic Biology to Battle Mpox," highlighted TNX-801, a horsepox-based live virus vaccine for mpox prevention.
TNX-801, designed for percutaneous administration, has shown promise in animal studies. It demonstrated single-dose immune protection against mpox challenges with improved tolerability compared to traditional vaccinia vaccines.
Tonix Pharmaceuticals has unveiled data on its mpox vaccine platform at a symposium honoring collaborator Dr. David Evans at the University of Alberta. The presentation, "Using Synthetic Biology to Battle Mpox," highlighted TNX-801, a horsepox-based live virus vaccine for mpox prevention.
TNX-801, designed for percutaneous administration, has shown promise in animal studies. It demonstrated single-dose immune protection against mpox challenges with improved tolerability compared to traditional vaccinia vaccines.
This research underscores Tonix's innovative approach to vaccine development, utilizing synthetic biology to address the ongoing global mpox threat. The full presentation is available on Tonix's website, offering insights into this potential advancement in mpox prevention.